


EXHIBIT A

 An official website of the United States government
[Here's how you know](#)



MENU

Thank you for visiting FOIA.gov, the government's central website for FOIA. We'll continue to make improvements to the site and look forward to your input. Please submit feedback to National.FOIAPortal@usdoj.gov.

Submission ID: 880716

Success!

Your FOIA request has been created and is being sent to the Center for Medicare and Medicaid Services.

You'll hear back from the agency confirming receipt in the coming weeks using the contact information you provided. If you have questions about your request, feel free to reach out to the agency FOIA personnel using the information provided below.

Contact the agency

Hugh Gilmore, FOIA Officer

410-786-5353

hugh.gilmore@cms.hhs.gov

FOIA Requester Service Center

410-786-5353

Joseph Tripline, FOIA Public Liaison

410-786-5353


joseph.tripline@cms.hhs.gov

Hugh Gilmore, FOIA Officer, North Building, Room C5-11-06
7500 Security Boulevard
Baltimore, MD 21244
FOIA_Request@cms.hhs.gov

Request summary

Request submitted on **September 28, 2023**.

The confirmation ID for your request is **880716**.

 The confirmation ID is only for identifying your request on FOIA.gov and acts as a receipt to show that you submitted a request using FOIA.gov. This number does not replace the information you'll receive from the agency to track your request. In case there is an issue submitting your request to the agency you selected, you can use this number to help.

Contact information

Name

Olivia Benjamin

Mailing address

312 Shawmut Ave.
Apt. 5
Boston, MA 02118
United States

Phone number

6172263165

Company/organization

VRA Enterprises, LLC

Email

obenjamin@foley.com

Your request

1. VRA Enterprises, LLC requests all documents relating to Medicare’s demonstration program (announced by the Centers for Medicare & Medicaid Services (“CMS”) April 4, 2022) covering over-the-counter COVID-19 tests (the “Demonstration”), including but not limited to: (a) all documents sufficient to articulate all prerequisites for providing over-the-counter test kits to Medicare Part B beneficiaries under the Demonstration; (b) all communications regarding whether email outreach to Medicare Part B beneficiaries is permissible under the Demonstration; (c) all documents, guidance, and communication regarding whether solicitation of Medicare Part B beneficiaries is permissible under the Demonstration; (d) all communications regarding whether participants may provide Medicare Part B beneficiaries with recurring monthly over-the-counter COVID-19 tests at a beneficiary’s request under the Demonstration; (e) all guidance, communications, and documents regarding what, if any, requirements apply before a beneficiary may receive recurring monthly over-the-counter COVID-19 tests; (f) all guidance, communications, and documents regarding what, if any, restrictions apply to advertising for provision of over-the-counter COVID-19 test kits under the Demonstration; and (g) what, if any, evaluation of necessity must be done before providing Medicare Part B beneficiaries with over-the-counter COVID-19 test under the Demonstration 2. All drafts of guidance, public facing materials, websites, and other content or communications describing the Demonstration; 3. All documents and communications with any government agency, including but not limited to the Department of Justice (“DOJ”), the Department of Health & Human Services (“HHS”) Office of Inspector General, the White House, Congress, the Government Accountability Office, regarding the Demonstration and any applicable rules, regulations, or guidance; 4. All documents relating to the HHS or CMS’s suspension of payments or pre-payment review of any healthcare provider for the provision of over-the-counter COVID-19 tests; 5. All documents relating to CMS’s December 6, 2022, decision to suspend payments to VRA Enterprises, LLC (NPI: 1043636921) (the “Pharmacy”) including but not limited to: (a) all communications and documents relating in any way to the decision to suspend the Pharmacy’s payments; (b) all communications demonstrating HHS Office of Inspector General consultation relating to the Pharmacy as required by 42 C.F.R. §§ 405.371(a)(2), 405.372(a)(4)(i); (c) all communications demonstrating DOJ consultation under 42 C.F.R. §§ 405.371(a)(2), 405.372(a)(4)(i), and all documents and communications relating to the decision of whether or not to consult DOJ relating to the Pharmacy’s payment suspension; and (d) all recordings or documents relating to beneficiary interviews and witness interviews conducted, and hotline complaints received, relating to the Pharmacy’s provision of over-the-counter COVID-19 tests under the Demonstration. 6. All documents relating to

CMS's decision to continue to suspend payments to the Pharmacy despite the Pharmacy's rebuttal submissions, including but not limited to all communications relating to the Pharmacy's rebuttal.

Fees

What type of requester are you?

other

Fee waiver

no

The amount of money you're willing to pay in fees, if any

2500

Request expedited processing

Expedited processing

no



FOIA.gov

CONTACT

Office of Information Policy (OIP)
U.S. Department of Justice
441 G St, NW, 6th Floor
Washington, DC 20530
E-mail: National.FOIAPortal@usdoj.gov

Hero image credit CC3.0

| FREQUENTLY ASKED QUESTIONS

| [DEVELOPER RESOURCES](#)

| [AGENCY API SPEC](#)

| [FOIA CONTACT DOWNLOAD](#)

| [FOIA DATASET DOWNLOAD
ACCESSIBILITY](#)

| [PRIVACY POLICY](#)

| [POLICIES & DISCLAIMERS](#)

| [JUSTICE.GOV](#)

| [USA.GOV](#) 